CoChat

Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study.

Open access
Petek, Bojana, Häbel, Henrike, Xu, Hong, Villa-Lopez, Marta, Kalar, Irena, Hoang, Minh Tuan, Maioli, Silvia, Pereira, Joana B., Mostafaei, Shayan, Winblad, Bengt, Gregoric Kramberger, Milica, Eriksdotter, Maria, Garcia-Ptacek, Sara · 2023 · Alzheimer's Research & Therapy

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Background: Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. Objective: To explore the association between the use of lipid-lowering medications and cognitive decline over time in a cohort of patients with AD or mixed dementia with indication for lipid-lowering treatment. Methods: A longitudinal cohort study using the Swedish Registry for Cognitive/Dementia Disorders, linked with other Swedish national registries. Cognitive trajectories evaluated with mini-mental state examination (MMSE) were compared between statin users and non-users, individual statin users, groups of statins and non-statin lipid-lowering medications using mixed-effect regression models with inverse probability of drop out weighting. A dose-response analysis included statin users compared to non-users. Results: Our cohort consisted of 15,586 patients with mean age of 79.5 years at diagnosis and a majority of women (59.2 %). A dose-response effect was demonstrated: taking one defined daily dose of statins on average was associated with 0.63 more MMSE points after 3 years compared to no use of statins (95% CI: 0.33;0.94). Simvastatin users showed 1.01 more MMSE points (95% CI: 0.06;1.97) after 3 years compared to atorvastatin users. Younger (< 79.5 years at index date) simvastatin users had 0.80 more MMSE points compared to younger atorvastatin users (95% CI: 0.05;1.55) after 3 years. Simvastatin users had 1.03 more MMSE points (95% CI: 0.26;1.80) compared to rosuvastatin users after 3 years. No differences regarding statin lipophilicity were observed. The results of sensitivity analysis restricted to incident users were not consistent. Conclusions: Some patients with AD or mixed dementia with indication for lipid-lowering medication may benefit cognitively from statin treatment; however, further research is needed to clarify the findings of sensitivity analyses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-023-01360-0

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Interaction between the patient’s and medication’s characteristics potentially influence the cognitive effects of statins. Two separate cholesterol pools in the body are thought to be connected to the risk of Alzheimer’s disease (AD), central and peripheral. The brain penetration of statins has been attributed to different factors linked to BBB crossing (lipophilicity of a statin, chemical structure, molecular weight and size of the molecule, different transporters and their genetic polymorphisms). The structure of the barrier itself additionally influences the permeability of statins and is affected by aging, neurodegenerative processes and possibly, peripheral hypercholesterolemia. The overall cognitive effects of statins are likely a result of their central and peripheral actions and are connected to the time of intervention in life and the pathogenesis of AD. Moreover, an interaction of comorbidities and comedication, a sufficient time of treatment and dosages are important. In midlife, protective effect of statins against AD could be achieved through lowering the metabolic risk of hyperlipidaemia. BBB blood–brain barrier, AD Alzheimer’s disease
Fig. 1 Interaction between the patient’s and medication’s characteristics potentially influence the cognitive effects of statins. Two separate cholesterol pools in the body are thought to be connected to the risk of Alzheimer’s disease (AD), central and peripheral. The brain penetration of statins has been attributed to different factors linked to BBB crossing (lipophilicity of a statin, chemical structure, molecular weight and size of the molecule, different transporters and their genetic polymorphisms). The structure of the barrier itself additionally influences the permeability of statins and is affected by aging, neurodegenerative processes and possibly, peripheral hypercholesterolemia. The overall cognitive effects of statins are likely a result of their central and peripheral actions and are connected to the time of intervention in life and the pathogenesis of AD. Moreover, an interaction of comorbidities and comedication, a sufficient time of treatment and dosages are important. In midlife, protective effect of statins against AD could be achieved through lowering the metabolic risk of hyperlipidaemia. BBB blood–brain barrier, AD Alzheimer’s diseaseCC BY · PubMed Central
Fig. 2 Flowchart of study participants selection. Hyperlipid patients with AD or mixed dementia, registered in SveDem from 2007 to 2018 were included in the study. Among these, we compared cognitive trajectories over time, evaluated with MMSE, in different comparison groups: (1) statin users vs non-users of statins, (2) simvastatin users vs atorvastatin users, (3) simvastatin users vs rosuvastatin users, (4) lipophilic statin users vs hydrophilic statin users, (5) fungal statin users vs synthetic statin users and (6) non-statin lipid-lowering medications users vs statin users
Fig. 2 Flowchart of study participants selection. Hyperlipid patients with AD or mixed dementia, registered in SveDem from 2007 to 2018 were included in the study. Among these, we compared cognitive trajectories over time, evaluated with MMSE, in different comparison groups: (1) statin users vs non-users of statins, (2) simvastatin users vs atorvastatin users, (3) simvastatin users vs rosuvastatin users, (4) lipophilic statin users vs hydrophilic statin users, (5) fungal statin users vs synthetic statin users and (6) non-statin lipid-lowering medications users vs statin usersCC BY · PubMed Central
Fig. 3 Cognitive decline, evaluated with change in MMSE score over time, in statin users compared to non-users of statins. The graph shows the association between increasing doses of statin treatment and MMSE over time, as predicted from the model. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities and comedication, with inverse probability weighting. DDD defined daily dose. DDD is defined by the World Health Organization as the assumed average maintenance daily dose of a medication for its primary indication in adults. Yearly visit 1 represent the first MMSE measurement (baseline)
Fig. 3 Cognitive decline, evaluated with change in MMSE score over time, in statin users compared to non-users of statins. The graph shows the association between increasing doses of statin treatment and MMSE over time, as predicted from the model. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities and comedication, with inverse probability weighting. DDD defined daily dose. DDD is defined by the World Health Organization as the assumed average maintenance daily dose of a medication for its primary indication in adults. Yearly visit 1 represent the first MMSE measurement (baseline)CC BY · PubMed Central
Fig. 4 Cognitive decline, evaluated with change in MMSE score over time, in simvastatin compared to atorvastatin users. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities and comedication, with inverse probability weighting. Yearly visit 1 represent the first MMSE measurement (baseline)
Fig. 4 Cognitive decline, evaluated with change in MMSE score over time, in simvastatin compared to atorvastatin users. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities and comedication, with inverse probability weighting. Yearly visit 1 represent the first MMSE measurement (baseline)CC BY · PubMed Central
Fig. 5 Cognitive decline, evaluated with change in MMSE scores over time, in simvastatin compared to rosuvastatin users. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities, and co-medication, with inverse probability weighting. Yearly visit 1 represent the first MMSE measurement (baseline)
Fig. 5 Cognitive decline, evaluated with change in MMSE scores over time, in simvastatin compared to rosuvastatin users. Linear mixed-effects regression model, adjusted for demographic characteristics, comorbidities, and co-medication, with inverse probability weighting. Yearly visit 1 represent the first MMSE measurement (baseline)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Cited by

See all 76

Metadata

Authors
Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., Gregoric Kramberger, M., Eriksdotter, M., & Garcia-Ptacek, S.
Affiliations
  • University of Ljubljana (SI)
  • Karolinska Institutet (SE)
  • Karolinska University Hospital (SE)
Corresponding author
Petek, Bojana
Venue
Alzheimer's Research & Therapy
Published
2023-12-20
Volume
15
Issue
1
Pages
220-220
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4389966265
Cited by
65
References
72
Citations by year
2026: 18 · 2025: 34 · 2024: 13
FWCI
13.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Stiftelsen Dementia
  • Margaretha af Ugglas Foundation
  • Health, Medicine and Technique grants from the Stockholm Region and Kungliga Tekniska Högskolan
  • Johanniterorden i Sverige/Swedish Order of St John
  • Medicinska Forskningsrådet (2020-02014, 2022-01425)
  • Karolinska Institutet Research Foundation
  • Karolinska Institutet Foundation for Diseases of Aging
  • The Erling Persson foundation
  • New Innovative Research grants
  • Innovative ways to fight Alzheimer´s disease - Leif Lundblad Family and others
  • Karolinska Institute
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
statins, cognitive decline, Alzheimer's disease, mixed dementia, lipid-lowering drugs, cholesterol homeostasis, simvastatin, atorvastatin, rosuvastatin, dose-response relationship, brain cholesterol metabolism, cognitive trajectories
MeSH terms
Atorvastatin, Mixed Dementias, Aged, Alzheimer Disease, Cholesterol, Female, Humans, Longitudinal Studies, Cohort Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. https://app.cochat.ai/papers/10.1186/s13195-023-01360-0
The paper
Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., Gregoric Kramberger, M., Eriksdotter, M., & Garcia-Ptacek, S. (2023). Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-023-01360-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.